{"analyses":[{"ciLowerLimit":"0.62","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.01","groupDescription":"Hazard ratio is obtained from the stratified Pike estimator.","groupIds":["OG000","OG001"],"nonInferiorityComment":"A hazard ratio \\<1 indicates a lower risk with dabrafenib + trametinib compared with Placebo.","nonInferiorityType":"SUPERIORITY","pValue":"0.063","paramType":"Hazard Ratio, log","paramValue":"0.80","statisticalComment":"Hazard Ratio and p-value from stratified log-rank test are adjusted for randomized strata: Disease stage and BRAF mutation status.","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"N/A: Not Estimable due to number of events censored","groupId":"OG000","lowerLimit":"120.7","upperLimit":"NA","value":"NA"},{"comment":"N/A: Not Estimable due to number of events censored","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"438"},{"groupId":"OG001","value":"432"}],"units":"Participants"}],"description":"Overall Survival (OS) was defined as the interval from randomization to the date of death, irrespective of the cause of death. Censoring was performed using the date of last known contact for those who were alive at the time of analysis.","dispersionType":"Full Range","groups":[{"description":"Subjects received dabrafenib (150 mg twice daily) and trametinib (2 mg once daily) orally for 12 months.","id":"OG000","title":"Dabrafenib and Trametinib Combination Therapy"},{"description":"Subjects received matching placebos orally for 12 months","id":"OG001","title":"Dabrafenib and Trametinib Placebos"}],"paramType":"MEDIAN","populationDescription":"Intent-to-Treat (ITT) Population","reportingStatus":"POSTED","timeFrame":"Approximately 10 years","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}